MSAT Training Specialist jobs in United States
cer-icon
Apply on Employer Site
company-logo

Capricor Therapeutics, Inc. · 2 months ago

MSAT Training Specialist

Capricor Therapeutics is a biotechnology company dedicated to advancing transformative cell and exosome-based therapies for rare diseases. As an MSAT Training Specialist, you will ensure operational excellence and GMP compliance by designing training programs, mentoring personnel, and maintaining documentation for regulatory readiness.

BiotechnologyHealth CareMedicalTherapeutics

Responsibilities

Develop and deliver training on GMP cell culture, cell counting, and aseptic techniques
Collaborate with subject matter experts to identify training needs and align with regulatory best practices
Mentor manufacturing personnel to foster professional growth and GMP adherence
Maintain and update SOPs, batch records, and technical documentation
Support investigations through root cause analysis, impact assessments, and CAPAs
Organize and maintain training lab, including supplies and equipment setup
Partner with QA and Manufacturing for seamless workflow integration
Support Manufacturing Operations inside an ISO7 cleanroom, including performing aseptic operations, process verification, and providing hands-on training

Qualification

GMP complianceAseptic techniquesCell culture manufacturingDocumentation systemsCommunication skillsMS Office proficiencyOrganizational skillsPresentation skillsCollaborative workIndependent work

Required

Bachelor's degree in life sciences or equivalent experience
1–3 years in a GMP environment, preferably in cell culture manufacturing
Strong knowledge of aseptic techniques, cell counting, and GMP production
Excellent communication, presentation, and organizational skills
Ability to work independently and collaboratively in a dynamic setting
Proficiency in documentation systems and MS Office

Company

Capricor Therapeutics, Inc.

twittertwitter
company-logo
Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients’ lives.

Funding

Current Stage
Public Company
Total Funding
$329.5M
Key Investors
Nippon ShinyakuNational Institutes of HealthCalifornia Institute for Regenerative Medicine
2025-12-05Post Ipo Equity· $150M
2024-10-17Post Ipo Equity· $75M
2024-09-17Post Ipo Equity· $15M

Leadership Team

leader-logo
AJ Bergmann
Chief Financial Officer
linkedin
Company data provided by crunchbase